OCE-205 is under clinical development by Ocelot Bio and currently in Phase II for Hepatorenal Syndrome. According to GlobalData, Phase II drugs for Hepatorenal Syndrome have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how OCE-205’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OCE-205 overview

OCE-205 is under development for the treatment of hepatorenal syndrome with acute kidney injury (HRS-AKI) and ascites. The drug candidate is a peptide therapeutic. It is administered through intravenous route as solution. It acts by targeting vasopressin V1a receptor.

Ocelot Bio overview

Ocelot Bio is a clinical-stage biopharmaceutical company focused on the development of therapeutics for patients with liver disease. Ocelot Bio is headquartered in San Diego, California, the US.

For a complete picture of OCE-205’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.